Regeneron stock gains pipeline focus from durable CIDEB data
Published on 11/12/2026 at 16:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCIDEB data broaden the pipeline case
- A single dose reduced liver fat by 58% to 80% at week 36 in the early MASLD study.
- Regeneron is advancing CIDEBsiRNA through recruiting Phase 2a, Phase 2b and Phase 3 trials.
- The candidate remains investigational, leaving regulatory efficacy and longer-term outcomes unresolved.
Regeneron Pharmaceuticals has added a new clinical catalyst to its pipeline after first-in-human data for CIDEBsiRNA showed durable liver-fat reductions in adults with metabolic dysfunction-associated steatotic liver disease. The findings were announced on November 8 and presented at the AASLD The Liver Meeting 2026, with simultaneous publication in The New England Journal of Medicine.
Regeneron stock traded at 865.05 euros on Lang & Schwarz at 16:31 CET on Thursday, November 12, 2026. That was 1.27% below the 876.20-euro Lang & Schwarz quote cited in the company's November 12 report at 14:02 CET, a separate comparison from the Xetra session measure.
Early data support liver pipeline
In the Phase 1/2 study, 30 participants received one subcutaneous CIDEBsiRNA dose across four dose levels and 10 received placebo. Safety and tolerability were the primary objectives, while liver fat and liver-injury markers were secondary measures, according to Regeneron's announcement.
At week 36, liver fat fell 58% to 80% among treated participants, measured by MRI-PDFF, compared with a 2.9% mean reduction for placebo. Liver fat fell below 5% in 62% of CIDEBsiRNA recipients and in none of the placebo group. Regeneron also reported that 93% of treated participants with week-36 data achieved at least a 30% reduction in liver fat.
Development risk remains high
Mean ALT levels declined across all doses, while AST changes moved in the same direction. Adverse-event rates were generally similar between the treatment and placebo groups, and the company reported no trial discontinuations among CIDEBsiRNA recipients.
The program is now being evaluated in recruiting Phase 2a, Phase 2b and Phase 3 studies. Those trials must show whether the early MRI-based improvements translate into durable effects on liver injury, disease progression and tissue-level outcomes. Regeneron said the treatment remains investigational and has not been evaluated by any regulatory authority.
Regeneron Pharmaceuticals
- ISIN: US75886F1075
- Ticker: REGN
- Sector: Healthcare
- Industry: Biotechnology
- Lang & Schwarz quote: 865.05 euros at 16:31 CET on Thursday, November 12, 2026
The S&P 500 provides the relevant U.S. market backdrop for Regeneron stock.
